Risk of Esophageal and Gastric Cancer After Bariatric Surgery
JAMA Surgery · 01.03.2023 · 158 (3) · 264
DOI: 10.1001/jamasurg.2022.6998 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Surgery, erschienen am 01.03.2023. Verfasst von Andrea Lazzati und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Centre Hospitalier Intercommunal de Créteil, Créteil, France. Hauptthemen laut MEDLINE: Obesity, Morbid, Esophageal Neoplasms, Stomach Neoplasms, Bariatric Surgery. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Bariatric surgery has been associated with a reduced risk of cancer in individuals with obesity. The association of bariatric surgery with esophageal and gastric cancer is still controversial, however.
Objective
To compare the incidence of esophageal and gastric cancer between patients with obesity who underwent bariatric surgery and those who did not (control group). Design, Setting, and Participants This cohort study obtained data from a national discharge database, including all surgical centers, in France from January 1, 2010, to December 31, 2017. Participants included adults (aged ≥18 years) with severe obesity who underwent bariatric surgery (surgical group) or who did not (control group). Baseline characteristics were balanced between groups using nearest neighbor propensity score matching with a 1:2 ratio. The study was conducted from March 1, 2020, to June 30, 2021. Exposures Bariatric surgery (adjustable gastric banding, gastric bypass, and sleeve gastrectomy) vs no surgery. Main Outcomes and Measures The main outcome was incidence of esophageal and gastric cancer. A secondary outcome was overall in-hospital mortality.
Results
A total of 303 709 patients who underwent bariatric surgery (245 819 females [80.9%]; mean [SD] age, 40.2 [11.9] years) were matched 1:2 with 605 140 patients who did not receive surgery (500 929 females [82.8%]; mean [SD] age, 40.4 [12.5] years). After matching, the 2 groups of patients were comparable in terms of age, sex, and comorbidities (standardized mean difference [SD], 0.05 [0.11]), with some differences in body mass index. The mean follow-up time was 5.62 (2.20) years in the control group and 6.06 (2.31) years in the surgical group. A total of 337 patients had esophagogastric cancer: 83 in the surgical group and 254 in the control group. The incidence rates were 6.9 per 100 000 population per year for the control group and 4.9 per 100 000 population per year for the surgical group, resulting in an incidence rate ratio of 1.42 (95% CI, 1.11-1.82; P = .005). The hazard ratio (HR) of cancer incidence was significantly in favor of the surgical group (HR, 0.76; 95% CI, 0.59-0.98; P = .03). Overall mortality was significantly lower in the surgical group (HR, 0.60; 95% CI, 0.56-0.64; P < .001). Conclusions and Relevance In this large, nationwide cohort of patients with severe obesity, bariatric surgery was associated with a significant reduction of esophageal and gastric cancer incidence and overall in-hospital mortality, which suggests that bariatric surgery can be performed as treatment for severe obesity without increasing the risk of esophageal and gastric cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of General Surgery, Centre Hospitalier Intercommunal de Créteil, Créteil, France.
- Institut National de la Santé et de la Recherche Médicale, Mondor Institute for Biomedical Research U955, Université Paris-Est Créteil, Créteil, France.
- Assistance Publique-Hôpitaux de Paris, Service de Chirurgie Digestive, Oesogastrique Et Bariatrique, Hôpital Bichat Claude Bernard, Paris, France.
- Université of Paris-Cité, Paris, France.
- Institut National de la Santé e de la Recherche Biomédicale, Paris, France.
- Clinical Research Center, Centre Hospitalier Intercommunal de Créteil, Créteil, France.
Zitieren
APA
Lazzati, A., Poghosyan, T., Touati, M., Collet, D., & Gronnier, C. (2023). Risk of Esophageal and Gastric Cancer After Bariatric Surgery. JAMA Surgery, 158(3), 264. https://doi.org/10.1001/jamasurg.2022.6998
Vancouver
Lazzati A, Poghosyan T, Touati M, Collet D, Gronnier C. Risk of Esophageal and Gastric Cancer After Bariatric Surgery. JAMA Surgery. 2023;158(3):264. doi:10.1001/jamasurg.2022.6998
BibTeX
@article{Lazzati2023,
author = {Lazzati, Andrea and Poghosyan, Tigran and Touati, Marwa and Collet, Denis and Gronnier, Caroline},
title = {Risk of Esophageal and Gastric Cancer After Bariatric Surgery},
journal = {JAMA Surgery},
year = {2023},
volume = {158},
number = {3},
pages = {264},
doi = {10.1001/jamasurg.2022.6998}
}
EUVIMED